title: [Asymptomatic acute cytolytic hepatitis due to fluindione and associated with resistance to treatment: a case report and review of the literature].
abstract: The authors report a case of asymptomatic acute cytolytic hepatitis due to fluindione (Previscan) associated with relative and selective resistance to this drug prescribed as a relay of heparin therapy for deep venous thrombosis following immobilisation of a sprained ankle in a 22 year-old patient. The main complications of oral anticoagulants are bleeding. Very severe immuno-allergic complications, especially hepatic, have been described with phenindione therapy. A review of the literature revealed a very low incidence of fluindione-induced hepatitis (7 cases), only two of which were fully documented since the commercialization of this molecule in 1971. No fatalities were reported: resistance to the treatment seemed to be associated. The exact mechanism (toxicity or immuno-allergy) has not been determined although the fact that fluindione is one of the indanedione family is in favour of the latter hypothesis.
authors.affiliation: Service d'hépato-gastro-entérologie, CHA H. Larrey, Toulouse.
authors.forename: J P
authors.initials: JP
authors.lastname: Penot
authors.forename: P
authors.initials: P
authors.lastname: Fontenelle
authors.forename: D
authors.initials: D
authors.lastname: Dorleac
mesh_terms: D000208:Acute Disease; D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D006801:Humans; D008297:Male; D010630:Phenindione / Q000009:adverse effects / Q000031:analogs & derivatives*; D017211:Treatment Failure
chemical_list: D000925:Anticoagulants; D010630:Phenindione; C017673:fluindione